ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01565096
Recruitment Status : Unknown
Verified March 2012 by ikfe-CRO GmbH.
Recruitment status was:  Recruiting
First Posted : March 28, 2012
Last Update Posted : March 28, 2012
Sponsor:
Collaborators:
Novartis Pharmaceuticals
IKFE Institute for Clinical Research and Development
Information provided by (Responsible Party):
ikfe-CRO GmbH

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : November 2012
  Study Completion Date : No date given